HSIC Stock Analysis — Henry Schein
Sector: Healthcare Distribution
AI Verdict
HSIC trades at 14.5x next year's earnings with a huge 60.4% EPS growth forecast—this is cheap for the growth on offer, and the moat from logistics and software integration makes those forecasts more credible than most.
Competitive Moat
Henry Schein dominates dental and medical supply distribution with a vast logistics network and exclusive supplier relationships, making it difficult for smaller players to compete on price or service. Its integrated software and practice management solutions further lock in customers, creating switching costs.
Summary
Henry Schein is notable right now for an expected 60.4% jump in earnings next year while trading at just 14.5x forward earnings.
Where It Stands
HSIC has returned 16.18% over the past year, sits at a neutral RSI of 53.8, and trades at 14.5x forward earnings versus the healthcare sector median of 22x.
Key Metrics
- RSI: 53.8 — Neutral
- Trailing P/E: 23.3x
- Forward P/E: 14.5x
- PEG Ratio: 0.38
- Earnings Growth: +0.6%
- Revenue Growth: +0.0%
- Market Cap: $8.7B
- 1-Year Return: 16.18%
- 52-Week High: $89.29
- 52-Week Low: $61.95
Analyst Consensus
13 Buy · 8 Hold · 1 Sell (22 analysts)
Bull Case
With consensus calling for 60.4% forward EPS growth and a trailing PEG of 0.38, the stock is priced cheaply relative to its expected growth.
Bear Case
If the forward P/E reverts back up to the sector median of 22x without earnings materializing, the stock could see a sharp pullback from current expectations.
Catalyst to Watch
Watch for upcoming earnings reports—if the company delivers on the 60.4% EPS growth forecast, it could justify further multiple expansion.